Dr Simon Hughes

Urologic oncologist, Consultant Clinical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust
  • London, GB
  • En
  • Best at: Prostate Cancer, Bladder Cancer

Dr Simon Hughes is Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust, and an Honorary Senior Lecturer at King’s College London School of Medical Education (GKT Medical School). He specialises in the treatment of Urological cancers: Bladder Cancer, Prostate Cancer, Radiotherapy for other Urological Cancers, SABR/Cyberknife (for Urological cancers). Simon Hughes trained at Guy’s and St Thomas’ Hospitals Medical School, where he also gained a BSc with First Class honours (Anatomy). His specialist training in Clinical Oncology included posts at The Middlesex Hospital, University College London Hospitals, and Guy’s & St. Thomas’ Hospitals. He also spent over 2 years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London developing novel radiotherapy techniques for the treatment of mobile tumours. Simon continues to have an active role in Research and Development. He led the Clinical Oncology and Radiotherapy Research and Development Team at Guy’s and St. Thomas’ Hospitals for 5 years, and was also Radiotherapy Clinical Trials Lead for the South East London Cancer Network during this period. His research interests include tumour motion, radiotherapy dose escalation, integration of functional imaging into radiotherapy planning, and the combination of novel agents with radiotherapy. He is the UK lead for the ENZARAD Study, and is a member of several Trial Management Groups / Data Monitoring Committees. Simon’s other main interest is medical education. He is the Education and Training Lead for King’s Health Partners Comprehensive Cancer Centre; an Associate Clinical Dean at King’s College London School of Medical Education; and is the Clinical Education and Training Lead for King’s College London School of Cancer and Pharmacological Sciences. Nationally, Simon is the Treasurer for the British Uro-oncology Group; and was the co-opted oncologist for the British Association of Urological Surgeons: Oncology Section Committee from 2013-2017. He is also a past President of the Oncology Section of the Royal Society of Medicine (2011-2012), and served on council for over 10 years.

Statistics.

Achievements of Dr Simon Hughes

Trustedoctor credentials
-
Clinical endorsements
27
Articles
171
Scientific
co-authors
Trustedoctor credentials
8
General specialty
10
Subspeciality
Languages

About.

Information about Dr Simon Hughes

Timeline
Place
Country
Position
Focus
2013
The Royal College of Physicians
United Kingdom
Fellowship
2010
University of London
United Kingdom
MD(Res)
2005
The Royal College of Radiologists
United Kingdom
Fellowship
2001
The Royal College of Physicians
United Kingdom
Membership
1997
University of London
United Kingdom
MBBS
Medicine
1994
University of London
United Kingdom
BSc
Anatomy & Basic Medical Sciences

Clinical Experience.

General speciality (5)
Patients per year
Patients total
general prostate tumour oncology
0-100
-
chemotherapy
0-100
-
immunotherapy
0-100
-
targeted therapy
0-100
-
clinical trials
0-50
-
Sub-speciality (7)
Patients per year
Patients total
benign prostatic hyperplasia
0-50
-
acinar adenocarcinoma
0-50
-
ductal adenocarcinoma
0-50
-
advanced prostate cancer
0-50
-
small cell prostate cancer
0-50
-
squamous cell cancer
0-50
-
transitional cell carcinoma
0-50
-
Techniques (2)
Patients per year
Patients total
stereotactic ablative radiotherapy (sabr)
0-50
-
cyberknife
0-50
-

Skills & Endorsements.

General specialty
general prostate tumour oncology
chemotherapy
immunotherapy
targeted therapy
Techniques
stereotactic ablative radiotherapy (sabr)
cyberknife
volumetric modulated arc therapy (vmat)

Academic research.

27
Total articles
  • surgery - 8
  • radiotherapy - 4
  • chemotherapy - 10
8
prostate cancer articles - Impact Factor
  • prostate neoplasms - 8
  • oncology therapy - 8
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.

Prostate cancer is the most frequent male cancer. Since the median age of diagnosis is 66 yr, many patients require both geriatric and urologic evaluation if treatment is to be tailored to individual circumstances including comorbidities and frailty.

Complexity of FGFR signalling in metastatic urothelial cancer.

Urothelial cancers (UC) are the fourth most common tumours worldwide after prostate (or breast), lung and colorectal cancer. Despite recent improvements in their management, UC remain an aggressive disease associated with a poor outcome. Following disease progression on first-line platinum-based chemotherapy, very few effective treatment options are available and none of them have shown significant improvement in overall survival. Alterations of the fibroblast growth factor receptor (FGFR) pathway including amplification, mutations and overexpression are common in UC. Pre-clinical data suggest that the presence of such dysregulations may confer sensitivity to FGFR inhibitors.

Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.

In 2010, the International Society of Geriatric Oncology (SIOG) developed treatment guidelines for men with prostate cancer who are older than 70 years old. In 2013, a new multidisciplinary SIOG working group was formed to update these recommendations. The consensus of the task force is that older men with prostate cancer should be managed according to their individual health status, not according to age. On the basis of a validated rapid health status screening instrument and simple assessment, the task force recommends that patients are classed into three groups for treatment: healthy or fit patients who should have the same treatment options as younger patients; vulnerable patients with reversible impairment who should receive standard treatment after medical intervention; and frail patients with non-reversible impairment who should receive adapted treatment.

Is there an antiandrogen withdrawal syndrome with enzalutamide?

To examine prostate-specific antigen (PSA) levels after enzalutamide discontinuation to assess whether an antiandrogen withdrawal syndrome (AAWS) exists with enzalutamide.

Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.

As recently as 2004, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) were limited, with docetaxel the only approved agent conferring a survival benefit. The therapeutic landscape is now very different, with several agents demonstrating prolonged survival since 2010. New agents for the treatment of mCRPC include sipuleucel-T, cabazitaxel, abiraterone acetate, enzalutamide and radium-223. All are now approved for use in this patient group, although the specific licensing terms vary between agents. In addition, denosumab may have utility in patients with bone metastases. A number of novel agents are also in development with promising initial results. However, because these treatment options have proliferated rapidly, there is currently a paucity of clinical evidence regarding their optimal sequencing. Selection of an appropriate treatment option should take into consideration disease characteristics, drug availability and patient choice. In summary, we discuss several new treatment options available for mCRPC and their integration into the current treatment paradigm.

Radical radiotherapy for high-risk prostate cancer in older men.

Historical data for older men with high-risk nonmetastatic prostate cancer treated with radiotherapy alone have demonstrated a 10-year prostate-cancer-specific mortality of around 30%. The development of dose escalation, using techniques such as intensity-modulated radiotherapy, has enabled more targeted delivery of treatment with improved efficacy and a reduction in the risk of toxicity compared with conventional radiotherapy. The combination of radiotherapy and androgen-deprivation therapy (ADT) has been shown to improve overall survival compared with radiotherapy or ADT alone without a significant increase in toxicity in patients with minimal comorbidities. There is evidence that patient age has only a marginal effect on genitourinary and gastrointestinal toxicities following radiotherapy. Further research has shown that although age does have an effect on the likelihood of sexual dysfunction after radiation therapy, there is no significant difference in the proportion of men aged ≥ 75 years who feel that sexual dysfunction is a moderate or serious problem before or 24 months after diagnosis. Radical radiotherapy is effective and well tolerated in senior men with high-risk prostate cancer and should be offered in combination with long-term ADT to patients with minimal comorbidities. In case of significant comorbid conditions, shorter durations of ADT may be considered.

Connections.

Map of connections

171
Scientific
co-authors
Our website unfortunately does not support your browser.<br/>Please click <a href="https://www.google.com/chrome/">here</a> to download and install modern browser.
Supported browsers: Firefox, Chrome, Opera.